Notogen, Inc.
- Biotech or pharma, therapeutic R&D
Notogen, Inc. is developing NTG-101 a unique breakthrough non-cellular molecular therapy for Degenerative Disc Disease (DDD). DDD causes chronic back and neck pain and is the leading cause of disability worldwide, affecting over 400 million people and for which there is no effective disease-modifying treatment. NTG-101 is a non-cellular intradiscal injection with compelling industry-leading large and small animal pre-clinical data.
Notogen is seeking a global or regional licensee/acquirer to complete the pre-IND work and clinical trials necessary for the approval and commercialization of NTG-101.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}